Savaysa (Edoxaban Tosylate) Patent Expiration, LOE Window & CMS Spending
Savaysa (Edoxaban Tosylate) by Daiichi Sankyo: FDA Orange Book core substance LOE 2027-04-18 (last listed 2028-03-28), 0 AB generics, $5.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Daiichi Sankyo |
| FDA Application & Pathway | N206316 (NDA) |
| Exclusivity / Cliff Horizon | Near-Term Cliff (2028-2030) |
| Core Active-Ingredient LOE Date | 2027-04-18 |
| Last Listed Patent or Exclusivity Date | 2028-03-28 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $5.6M |
| 2024 Medicare Part D Spend | $5.1M |
| 2024 Medicaid Spend | $512K |
| Reported Wholesale Price Change (CA SB 17) | 6 WAC filings (max 18.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.